참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 4-Bromophenol | HCID 7808 | — |
| 반응물 | 1-Methylpiperazine | HCID 53167 | — |
| 시약 | Lithium Hexamethyldisilazide | HCID 2733832 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 촉매 | 2,8,9-Triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo(3.3.3)undecane | HCID 4571243 | — |
| 용매 | Toluene | HCID 1140 | — |
| 생성물 | 4-(4-Methyl-1-piperazinyl)phenol | HCID 11622486 | 50.99% |
반응 단계
diacetoxypalladium (0.039 g, 0.17 mmol) was added in one portion to 4-bromophenol (3 g, 17.34 mmol) and 1-methylpiperazine (2.308 mL, 20.81 mmol) in toluene (87 mL) at 25°C under nitrogen. To this was added toluene (87 mL) then a solution of 2,8,9-triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo[3.3.3]undecane (0.123 mL, 0.35 mmol) in Toluene (1 mL) and finally 1M LITHIUM BIS(TRIMETHYLSILYL)AMIDE (39.9 mL, 39.88 mmol) in THF was added dropwise over 1 minute. The resulting mixture was stirred at 80 °C for 18 hours. The reaction was allowed to cool to room temperature, SiO2 (23g) was added and evaporated to dryness. The crude product was purified by flash silica chromatography (120g), elution gradient 0 to 10% MeOH in EtOAc. Pure fractions were evaporated to dryness to afford 4-(4-methylpiperazin-1-yl)phenol (1.700 g, 51.0 %) as a beige solid.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-8e16338c39aa405d9e6607bfaa8d820e |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|